Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2022 Oct 24

PMID 36278961

Authors

Ke Peng

Feifei Zhang

Yichen Wang

Pranshu Sahgal

Tianxia Li

Jin Zhou

Xiaoyan Liang

Yanxi Zhang

Nilay Sethi

Tianshu Liu

Haisheng Zhang

Adam J Bass

Affiliations

Soon will be listed here.

Abstract

Purpose: Diffuse gastric cancer (DGC) is an aggressive and frequently lethal subtype of gastric cancer. Because DGC often lacks genomic aberrations that indicate clear candidate therapeutic targets, it has been challenging to develop targeted therapies for this gastric cancer subtype. Our previous study highlighted the contribution of focal adhesion kinase (FAK) in the tumorigenesis of DGC and the potential efficacy of small-molecule FAK inhibitors. However, drug resistance to monotherapy often hinders the efficacy of treatment.

Experimental Design: We generated a genome-scale library of open reading frames (ORF) in the DGC model of Cdh1-/-RHOAY42C/+ organoids to identify candidate mechanisms of resistance to FAK inhibition. Compensatory activated pathways were also detected following treatment with FAK inhibitors. Candidates were investigated by cotargeting in vitro and in vivo experiments using DGC.

Results: We found that cyclin-dependent kinase 6 (CDK6) promoted FAK inhibitor resistance in ORF screen. In addition, FAK inhibitor treatment in DGC models led to compensatory MAPK pathway activation. Small-molecule CDK4/6 inhibitors or MAPK inhibitors effectively enhanced FAK inhibitor efficacy in vitro and in vivo.

Conclusions: Our data suggest that FAK inhibitors combined with MAPK inhibitors or CDK4/6 inhibitors warrant further testing in clinical trials for DGC.

Citing Articles

in enhancing the effect of defactinib on gastric cancer cells via the inhibition of FAK phosphorylation.

He X, Wang Y, Zhang Y, Sahu A, Almhanna K, Liu Y Transl Cancer Res. 2025; 13(12):6905-6918.

PMID: 39816536 PMC: 11730453. DOI: 10.21037/tcr-24-2049.

Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics.

Wu L, Jang S, Shapiro C, Fazlollahi L, Wang T, Ryeom S Target Oncol. 2024; 19(6):845-865.

PMID: 39271577 PMC: 11557641. DOI: 10.1007/s11523-024-01097-2.

Master Regulators of Causal Networks in Intestinal- and Diffuse-Type Gastric Cancer and the Relation to the RNA Virus Infection Pathway.

Tanabe S, Quader S, Cabral H, Perkins E, Yokozaki H, Sasaki H Int J Mol Sci. 2024; 25(16).

PMID: 39201509 PMC: 11354771. DOI: 10.3390/ijms25168821.

Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.

Zhang F, Sahu V, Peng K, Wang Y, Li T, Bala P Gut. 2024; 73(8):1280-1291.

PMID: 38621923 PMC: 11287566. DOI: 10.1136/gutjnl-2023-329686.

Roles and inhibitors of FAK in cancer: current advances and future directions.

Hu H, Wang S, Shang H, Lv H, Chen B, Gao S Front Pharmacol. 2024; 15:1274209.

PMID: 38410129 PMC: 10895298. DOI: 10.3389/fphar.2024.1274209.

References

Sebolt-Leopold J, Herrera R . Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4(12):937-47. DOI: 10.1038/nrc1503. View

Jiang H, Liu X, Knolhoff B, Hegde S, Lee K, Jiang H . Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Gut. 2019; 69(1):122-132. PMC: 7167297. DOI: 10.1136/gutjnl-2018-317424. View

Song X, Xu H, Wang P, Wang J, Affo S, Wang H . Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. J Hepatol. 2021; 75(4):888-899. PMC: 8453055. DOI: 10.1016/j.jhep.2021.05.018. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Jiang H, Hegde S, Knolhoff B, Zhu Y, Herndon J, Meyer M . Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016; 22(8):851-60. PMC: 4935930. DOI: 10.1038/nm.4123. View

Yadav B, Wennerberg K, Aittokallio T, Tang J . Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. Comput Struct Biotechnol J. 2016; 13:504-13. PMC: 4759128. DOI: 10.1016/j.csbj.2015.09.001. View

Jones S, Siu L, Bendell J, Cleary J, Razak A, Infante J . A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015; 33(5):1100-7. DOI: 10.1007/s10637-015-0282-y. View

Paradis J, Acosta M, Saddawi-Konefka R, Kishore A, Gomes F, Arang N . Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for -Driven Uveal Melanoma. Clin Cancer Res. 2021; 27(11):3190-3200. PMC: 8895627. DOI: 10.1158/1078-0432.CCR-20-3363. View

Sulzmaier F, Jean C, Schlaepfer D . FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014; 14(9):598-610. PMC: 4365862. DOI: 10.1038/nrc3792. View

10.

Feng X, Arang N, Rigiracciolo D, Lee J, Yeerna H, Wang Z . A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell. 2019; 35(3):457-472.e5. PMC: 6737937. DOI: 10.1016/j.ccell.2019.01.009. View

11.

Zhang C, Stockwell S, Elbanna M, Ketteler R, Freeman J, Al-Lazikani B . Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene. 2019; 38(30):5905-5920. PMC: 6756076. DOI: 10.1038/s41388-019-0850-2. View

12.

Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J . A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016; 77(5):997-1003. PMC: 4844649. DOI: 10.1007/s00280-016-3010-1. View

13.

Fallahi-Sichani M, Becker V, Izar B, Baker G, Lin J, Boswell S . Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol. 2017; 13(1):905. PMC: 5248573. DOI: 10.15252/msb.20166796. View

14.

Chen G, Gao C, Gao X, Zhang D, Kuan S, Burns T . Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. Mol Cancer Ther. 2017; 17(4):806-813. PMC: 5882543. DOI: 10.1158/1535-7163.MCT-17-0561. View

15.

Capelletto E, Bironzo P, Denis L, Koustenis A, Bungaro M, Novello S . Single agent VS-6766 or VS-6766 plus defactinib in -mutant non-small-cell lung cancer: the RAMP-202 phase II trial. Future Oncol. 2022; 18(16):1907-1915. DOI: 10.2217/fon-2021-1582. View

16.

Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M . CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017; 8:13897. PMC: 5227099. DOI: 10.1038/ncomms13897. View

17.

Miyoshi H, Stappenbeck T . In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat Protoc. 2013; 8(12):2471-82. PMC: 3969856. DOI: 10.1038/nprot.2013.153. View

18.

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

19.

Corcoran R, Andre T, Atreya C, Schellens J, Yoshino T, Bendell J . Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer. Cancer Discov. 2018; 8(4):428-443. PMC: 5882509. DOI: 10.1158/2159-8290.CD-17-1226. View

20.

Suski J, Braun M, Strmiska V, Sicinski P . Targeting cell-cycle machinery in cancer. Cancer Cell. 2021; 39(6):759-778. PMC: 8206013. DOI: 10.1016/j.ccell.2021.03.010. View